

Amendments to the Claims:

Cancel claims 1-15.

Add new claims 16-25.

A complete listing of the claims follows:

1-15. Cancelled

16. (New) A pharmaceutically active agent-releasing surface coating for a medical device comprising:

an interpenetrating polymeric network (IPN) and at least one pharmaceutically active agent wherein said at least one pharmaceutically active agent is present in said IPN in an inwardly decreasing concentration gradient.

17. (New) The pharmaceutically active agent-releasing surface coating for a medical device according to claim 16 wherein said IPN is a polyurea or a polyurethane.

18. (New) The pharmaceutically active agent-releasing surface coating for a medical device according to claim 16 wherein at least one pharmaceutically active agent is selected from the group consisting of anti-proliferatives, anti-inflammatories, ant-thrombogenic compounds, and antimicrobials.

19. (New) The pharmaceutically active agent-releasing surface coating for a medical device according to claim 18 wherein said anti-proliferative selected from the group consisting of nitric oxide, monoclonal antibodies and polypeptides.

20. (New) The pharmaceutically active agent-releasing surface coating for a medical device according to claim 16 wherein said medical device is selected from the group consisting of guide wires, catheters, and stents.

21. (New) A pharmaceutically active agent-releasing surface coating for a stent comprising:

an interpenetrating polymeric network (IPN) and at least one anti-proliferative wherein said at least one anti-proliferative is present in said IPN in an inwardly decreasing concentration gradient and wherein said anti-proliferative is useful in treating or inhibiting restenosis.

22. (New) The pharmaceutically active agent-releasing surface coating for a medical device according to claim 21 wherein said IPN is a polyurea or a polyurethane.

23. (New) The pharmaceutically active agent-releasing surface coating for a medical device according to claim 21 wherein said anti-proliferative is selected from the group consisting of nitric oxide, monoclonal antibodies and polypeptides.

24. (New) A stent having pharmaceutically active agent-releasing surface coating comprising:

an interpenetrating polymeric network (IPN) and at least one anti-proliferative wherein said at least one antiproliferative is present in said IPN in an inwardly decreasing concentration gradient and wherein said anti-proliferative is useful in treating or inhibiting restenosis and wherein said surface coating further comprises a polysaccharide selected from the group consisting of hyaluronic acid, heparin, enoxaprin and combinations thereof.

25. (New) A stent having pharmaceutically active agent-releasing surface coating comprising:

an interpenetrating polymeric network (IPN) and nitric oxide wherein said nitric oxide is present in said IPN in an inwardly decreasing concentration gradient.